Psychedelic Assisted Therapies

A study published in the Journal of Psychopharmacology has found that feelings of relaxation, rather than mystical experiences are the strongest predictor of positive outcomes in psychedelic-assisted therapy for treatment-resistant psychiatric disorders. Led by Gregor Hasler at Switzerland’s...

As election season dominated every aspect of American life – from relentless TV ads to heated debates on critical issues – many U.S. citizens found themselves grappling with heightened stress and anxiety. As Double Blind reported, in the wake of the election, the demand for psychedelics...

As the U.S. celebrates Veterans Day, more and more war vets are seeking alternative treatments for post-traumatic stress disorder (PTSD) in the hope of finding relief. Among the most promising therapies is psychedelic-assisted therapy, which has demonstrated significant potential in helping...

In a pioneering study funded by the UK Government, researchers at Imperial College London are set to examine the potential of psilocybin-assisted therapy to treat opioid addiction. As Leafie reported, this marks the first time that the UK government has backed research into using psilocybin for...

Starting in 2025, students at the California Institute of Integral Studies (CIIS) in San Francisco will be able to pursue a unique academic path: a bachelor's degree in psychedelics studies. This marks the first time an accredited institution in the United States has offered an undergraduate degree...

In an unexpected turn, some elite golfers are trading traditional pharmaceuticals for psychedelics like psilocybin and ayahuasca, hoping to gain a mental edge. As Double Blind reported, while both compounds are associated with altered states, they're increasingly being used in microdoses by golfers...

In a recent conversation on The Joe Rogan Experience, Elon Musk and Joe Rogan delivered a sharp critique of the pharmaceutical industry, bashing its history of prioritizing profit over public safety. Their discussion not only touched on well-known scandals like OxyContin and Vioxx but also ventured...

As Election Day 2024 unfolds, Massachusetts and Oregon are capturing national attention with pivotal ballot measures on psychedelics. Both states have the potential to reshape U.S. mental health treatment by advancing policies on substances like psilocybin and MDMA, part of the “psychedelic...

The Cannabist Company has launched a donation drive through Veterans Day to benefit the Weed for Warriors Project (WFW), a nonprofit dedicated to supporting holistic care for veterans, including access to medical cannabis. This initiative spans 12 U.S. markets—California, Colorado, Delaware,...

In a recent appearance on Joe Rogan's podcast, former President Donald Trump’s running mate JD Vance (R-OH) expressed newfound interest in exploring therapeutic psychedelics for veterans, prompted by Rogan's perspectives on the potential benefits and history of these substances. Vance...

Compass Pathways (NASDAQ:CMPS) has announced delays for two key Phase 3 clinical trials involving its psilocybin program, widely seen as a leader in the psychedelic drug development space. As Endpoint News reported, the unexpected timeline shifts, unveiled in the company's third-quarter earnings...

Federal agencies recently convened in a pivotal public meeting, hosted by the Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA), to discuss emerging treatments for post-traumatic stress disorder (PTSD), with a focus on the potential of psychedelics. As Lexology reported, the...

Eliza Dushku, known for roles in “Buffy the Vampire Slayer” and “Bring It On,” is turning her focus from Hollywood to health advocacy, leveraging her personal experience with psychedelic-assisted therapy to support Ballot Question 4 in Massachusetts. As Boston 25 News...

The global psychedelic drugs market is set for rapid expansion, with projections forecasting growth from $4.88 billion in 2023 to $10.2 billion by 2028, according to The Business Research Company. With a compound annual growth rate of 16.1%, this rise is largely driven by increased awareness of...

In a groundbreaking study published in Neuron, researchers at Johns Hopkins University uncovered how the psychedelic drug DOI (2,5-dimethoxy-4-iodoamphetamine) reduces anxiety by activating particular neurons in the brain. The research looks at a specific type of brain cell called parvalbumin-...